演題詳細

一般口演 / Oral Session

【E】一般口演 16 (Oral Session 16) :MDS:Clinical Research 3

print

日程
2013年10月11日(金)
時間
10:00 - 11:30
会場
第14会場 / Room No.14 (札幌市教育文化会館 3F 研修室305)
座長・司会
石川 隆之 (Takayuki Ishikawa):1
1:Department of Hematology, Kobe City Medical Center General Hospital, Japan
 
前へ戻る

The positive impact of azacitidine on survival of high-risk MDS

演題番号 : OS-1-82

竹田 淳恵 (June Takeda):1、数馬 安浩 (Yasuhiro Kazuma):1、長畑 洋佑 (Yosuke Nagahata):1、船山 由樹 (Yuki Funayama):1、山内 寛彦 (Nobuhiko Yamauchi):1、小野 祐一郎 (Yuichiro Ono):1、田端 淑恵 (Sumie Tabata):1、米谷 昇 (Noboru Yonetani):1、松下 章子 (Akiko Matsushita):1、石川 隆之 (Takayuki Ishikawa):1

1:Dept. of Hematology, Kobe City General Hospital, Japan

 

Objectives:Azicitidine (Aza) has shown its superiority over conventional care regimen in prolonging survival of high-risk MDS. To confirm the positive impact of Aza, we compared the outcome of high-risk MDS patients (pts) who received parental treatment.
Methods:The data of consecutive adult pts with high-risk MDS (RAEB or RAEB in T) in our institute within the period from 1st January, 2000, to 30th November 2012 was retrospectively analyzed.Survival was calculated after the introduction of parental chemotherapy. Survival analysis was done by Kaplan-Meier method. Cox regression model was applied for analyses.Result:A total of 122 pts were evaluated. The median follow-up period was 22 months (range 0-127 months). Male/female ratio was 94/28 and median age was 65 years old (yo) (29-84). According to the initial treatment, pts were divided into 4 groups(grp)- Aza grp (N = 26 median age:64.5 yo), low-dose Ara-C (LDAC) grp; (N = 68 median age:68.5 yo), intensive chemotherapy (IC) grp (N = 13 median age:68 yo), and up-front allogeneic hematopoietic stem cell transplantation (AHSCT) grp (N = 15 median age:51 yo).1 year survival rate was 69.8%, 25.0%, 38.9%, and 92.3% for each grp, respectively. As expected, Aza grp showed significantly superior overall survival (OS) compared with LDAC and IC grp (p=0.005). Among pts who did not underwent AHSCT, Aza grp also had positive impact on 1 year OS (p=0.009).Conclusion:This retrospective analysis confirmed that the introduction of Aza in the management of high-risk MDS certainly improved the outcome.

前へ戻る